DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
Identifieur interne : 001945 ( Ncbi/Curation ); précédent : 001944; suivant : 001946DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
Auteurs : Ap Im [États-Unis] ; Ar Sehgal [États-Unis] ; Mp Carroll [États-Unis] ; Bd Smith [États-Unis] ; A. Tefferi [États-Unis] ; De Johnson [États-Unis] ; M. Boyiadzis [États-Unis]Source :
- Leukemia [ 0887-6924 ] ; 2014.
Descripteurs français
- KwdFr :
- DNA (cytosine-5-)-methyltransferase (génétique), Humains, Isocitrate dehydrogenases (génétique), Leucémie aigüe myéloïde (génétique), Leucémie aigüe myéloïde (traitement médicamenteux), Mutation, Pronostic, Protéines nucléaires (génétique), Syndromes myélodysplasiques (génétique), Syndromes myéloprolifératifs (génétique), Tyrosine kinase-3 de type fms (génétique).
- MESH :
- génétique : DNA (cytosine-5-)-methyltransferase, Isocitrate dehydrogenases, Leucémie aigüe myéloïde, Protéines nucléaires, Syndromes myélodysplasiques, Syndromes myéloprolifératifs, Tyrosine kinase-3 de type fms.
- traitement médicamenteux : Leucémie aigüe myéloïde.
- Humains, Mutation, Pronostic.
English descriptors
- KwdEn :
- DNA (Cytosine-5-)-Methyltransferase (genetics), Humans, Isocitrate Dehydrogenase (genetics), Leukemia, Myeloid, Acute (drug therapy), Leukemia, Myeloid, Acute (genetics), Mutation, Myelodysplastic Syndromes (genetics), Myeloproliferative Disorders (genetics), Nuclear Proteins (genetics), Prognosis, fms-Like Tyrosine Kinase 3 (genetics).
- MESH :
- chemical , genetics : DNA (Cytosine-5-)-Methyltransferase, Isocitrate Dehydrogenase, Nuclear Proteins, fms-Like Tyrosine Kinase 3.
- drug therapy : Leukemia, Myeloid, Acute.
- genetics : Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders.
- Humans, Mutation, Prognosis.
Abstract
The development of effective treatment strategies for most forms of acute myeloid leukemia (AML) has languished for the past several decades. There are a number of reasons for this, but key among them is the considerable heterogeneity of this disease and the paucity of molecular markers that can be used to predict clinical outcomes and responsiveness to different therapies. The recent large-scale sequencing of AML genomes is now providing opportunities for patient stratification and personalized approaches to treatment that are based on individual mutational profiles. It is particularly notable that studies by The Cancer Genome Atlas and others have determined that 44% of patients with AML exhibit mutations in genes that regulate methylation of genomic DNA. In particular, frequent mutation has been observed in the genes encoding DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2), as well as Tet oncogene family member 2. This review will summarize the incidence of these mutations, their impact on biochemical functions including epigenetic modification of genomic DNA and their potential usefulness as prognostic indicators. Importantly, the presence of
Url:
DOI: 10.1038/leu.2014.124
PubMed: 24699305
PubMed Central: 4234093
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001642
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :001617
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001F16
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C25
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001C17
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001C17
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001945
Links to Exploration step
PMC:4234093Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en"><italic>DNMT3A</italic> and <italic>IDH</italic> mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies</title><author><name sortKey="Im, Ap" sort="Im, Ap" uniqKey="Im A" first="Ap" last="Im">Ap Im</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Sehgal, Ar" sort="Sehgal, Ar" uniqKey="Sehgal A" first="Ar" last="Sehgal">Ar Sehgal</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Carroll, Mp" sort="Carroll, Mp" uniqKey="Carroll M" first="Mp" last="Carroll">Mp Carroll</name><affiliation wicri:level="2"><nlm:aff id="A2">Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Smith, Bd" sort="Smith, Bd" uniqKey="Smith B" first="Bd" last="Smith">Bd Smith</name><affiliation wicri:level="2"><nlm:aff id="A3">The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology at the Johns Hopkins University, Baltimore, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology at the Johns Hopkins University, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tefferi, A" sort="Tefferi, A" uniqKey="Tefferi A" first="A" last="Tefferi">A. Tefferi</name><affiliation wicri:level="2"><nlm:aff id="A4">Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Johnson, De" sort="Johnson, De" uniqKey="Johnson D" first="De" last="Johnson">De Johnson</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Boyiadzis, M" sort="Boyiadzis, M" uniqKey="Boyiadzis M" first="M" last="Boyiadzis">M. Boyiadzis</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24699305</idno><idno type="pmc">4234093</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234093</idno><idno type="RBID">PMC:4234093</idno><idno type="doi">10.1038/leu.2014.124</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001642</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001642</idno><idno type="wicri:Area/Pmc/Curation">001617</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001617</idno><idno type="wicri:Area/Pmc/Checkpoint">001F16</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001F16</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001C25</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C25</idno><idno type="wicri:Area/PubMed/Curation">001C17</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C17</idno><idno type="wicri:Area/PubMed/Checkpoint">001C17</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C17</idno><idno type="wicri:Area/Ncbi/Merge">001945</idno><idno type="wicri:Area/Ncbi/Curation">001945</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main"><italic>DNMT3A</italic> and <italic>IDH</italic> mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies</title><author><name sortKey="Im, Ap" sort="Im, Ap" uniqKey="Im A" first="Ap" last="Im">Ap Im</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Sehgal, Ar" sort="Sehgal, Ar" uniqKey="Sehgal A" first="Ar" last="Sehgal">Ar Sehgal</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Carroll, Mp" sort="Carroll, Mp" uniqKey="Carroll M" first="Mp" last="Carroll">Mp Carroll</name><affiliation wicri:level="2"><nlm:aff id="A2">Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Smith, Bd" sort="Smith, Bd" uniqKey="Smith B" first="Bd" last="Smith">Bd Smith</name><affiliation wicri:level="2"><nlm:aff id="A3">The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology at the Johns Hopkins University, Baltimore, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology at the Johns Hopkins University, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tefferi, A" sort="Tefferi, A" uniqKey="Tefferi A" first="A" last="Tefferi">A. Tefferi</name><affiliation wicri:level="2"><nlm:aff id="A4">Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Johnson, De" sort="Johnson, De" uniqKey="Johnson D" first="De" last="Johnson">De Johnson</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Boyiadzis, M" sort="Boyiadzis, M" uniqKey="Boyiadzis M" first="M" last="Boyiadzis">M. Boyiadzis</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="ISSN">0887-6924</idno><idno type="eISSN">1476-5551</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DNA (Cytosine-5-)-Methyltransferase (genetics)</term><term>Humans</term><term>Isocitrate Dehydrogenase (genetics)</term><term>Leukemia, Myeloid, Acute (drug therapy)</term><term>Leukemia, Myeloid, Acute (genetics)</term><term>Mutation</term><term>Myelodysplastic Syndromes (genetics)</term><term>Myeloproliferative Disorders (genetics)</term><term>Nuclear Proteins (genetics)</term><term>Prognosis</term><term>fms-Like Tyrosine Kinase 3 (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>DNA (cytosine-5-)-methyltransferase (génétique)</term><term>Humains</term><term>Isocitrate dehydrogenases (génétique)</term><term>Leucémie aigüe myéloïde (génétique)</term><term>Leucémie aigüe myéloïde (traitement médicamenteux)</term><term>Mutation</term><term>Pronostic</term><term>Protéines nucléaires (génétique)</term><term>Syndromes myélodysplasiques (génétique)</term><term>Syndromes myéloprolifératifs (génétique)</term><term>Tyrosine kinase-3 de type fms (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA (Cytosine-5-)-Methyltransferase</term><term>Isocitrate Dehydrogenase</term><term>Nuclear Proteins</term><term>fms-Like Tyrosine Kinase 3</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Myeloid, Acute</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Leukemia, Myeloid, Acute</term><term>Myelodysplastic Syndromes</term><term>Myeloproliferative Disorders</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>DNA (cytosine-5-)-methyltransferase</term><term>Isocitrate dehydrogenases</term><term>Leucémie aigüe myéloïde</term><term>Protéines nucléaires</term><term>Syndromes myélodysplasiques</term><term>Syndromes myéloprolifératifs</term><term>Tyrosine kinase-3 de type fms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie aigüe myéloïde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Mutation</term><term>Prognosis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Mutation</term><term>Pronostic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">The development of effective treatment strategies for most forms of acute myeloid leukemia (AML) has languished for the past several decades. There are a number of reasons for this, but key among them is the considerable heterogeneity of this disease and the paucity of molecular markers that can be used to predict clinical outcomes and responsiveness to different therapies. The recent large-scale sequencing of AML genomes is now providing opportunities for patient stratification and personalized approaches to treatment that are based on individual mutational profiles. It is particularly notable that studies by The Cancer Genome Atlas and others have determined that 44% of patients with AML exhibit mutations in genes that regulate methylation of genomic DNA. In particular, frequent mutation has been observed in the genes encoding DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2), as well as Tet oncogene family member 2. This review will summarize the incidence of these mutations, their impact on biochemical functions including epigenetic modification of genomic DNA and their potential usefulness as prognostic indicators. Importantly, the presence of <italic>DNMT3A</italic>, <italic>IDH1</italic> or <italic>IDH2</italic> mutations may confer sensitivity to novel therapeutic approaches, including the use of demethylating agents. Therefore, the clinical experience with decitabine and azacitidine in the treatment of patients harboring these mutations will be reviewed. Overall, we propose that understanding the role of these mutations in AML biology will lead to more rational therapeutic approaches targeting molecularly defined subtypes of the disease.</p></div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001945 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001945 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= PMC:4234093
|texte= DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:24699305" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |